Logo

Mainz Biomed

Mainz Biomed Stock Spikes on Positive Data for mRNA-Enhanced Colorectal Cancer Screening Assay

In top-line data, Mainz Biomed's enhanced ColoAlert detected CRC with 94 percent sensitivity and 97 percent specificity, and advanced adenoma with 81 percent sensitivity.

Mainz Biomed Partners With German Diagnostic Laboratory to Offer ColoAlert Test

The collaboration with Ärztliches Labor Dr. Buhlmann will provide Mainz Biomed with greater access to Germany's private health insurance segment.

In Brief This Week: Illumina, Thermo Fisher, Tempus, Bionano Genomics, Danaher, More

News items for the week of Aug. 14, 2023

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.